The Registry for the Advancement of Deep Brain Stimulation (DBS) Therapy in Parkinson’s Disease (RAD-PD) is slated to launch in the fall of 2018. The registry’s primary aim is to identify best practices, adverse effects and health economics factors and disparities related to DBS therapy within a defined patient cohort. Analysis of this cohort has the potential to answer clinical questions limited by standard randomized controlled trial methodology for DBS.

The NPA will provide registry management while Neurotargeting, LLC provides technical management and support through its CranialCloud platform. NPA and Neurotargeting also sit on the registry’s steering committee along with representatives from the Parkinson Study Group and the Michael J. Fox Foundation, which is generously supporting this effort over the first two years. Representatives from industry also sit on the steering committee.

The registry recently completed a competitive enrollment process of identifying 10 participating centers for the first year. The first patients will be entered into the registry in the fall of 2018. More details about the RAD-PD are found here.